Interim results show promising activity for rezatapopt (PC14586) in patients with advanced ovarian cancer carrying the TP53 Y220C mutation.
Rezatapopt is a first-in-class oral drug designed to restore the function of the mutated p53 protein, a key tumor suppressor. By stabilizing this specific mutation, the drug helps cancer cells regain normal growth control, offering a targeted alternative to chemotherapy.
In heavily pretreated patients, the drug achieved an overall response rate of 44.4% and a disease control rate of about 76%. Responses occurred quickly, with a median time of 1.3 months, and lasted a median of 8.2 months. Benefits were consistent regardless of prior treatments.
The therapy was generally well tolerated, with mostly mild side effects such as nausea and fatigue. Blood tests also confirmed strong biological activity, supporting its targeted mechanism.